Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer.

Van Laar, Ryan K

Van Laar, Ryan K.

Affiliation

Van Laar RK; ChipDX LLC, PO Box 286874, New York, NY 10128, USA. ryan.vanlaar@chipdx.com

BMC Med Genomics ; 5: 30, 2012 Jul 02.

Article in En | MEDLINE | ID: mdl-22748043

Subject(s)

Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/genetics; Cisplatin/administration & dosage; Gene Expression Profiling; Genome, Human; Lung Neoplasms/drug therapy; Lung Neoplasms/genetics; Vinblastine/analogs & derivatives; Aged; Carcinoma, Non-Small-Cell Lung/mortality; Chemotherapy, Adjuvant; Female; Genomics; Humans; Lung/drug effects; Lung/pathology; Lung Neoplasms/mortality; Male; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine/administration & dosage; Vinorelbine

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vinblastine / Genome, Human / Cisplatin / Carcinoma, Non-Small-Cell Lung / Gene Expression Profiling / Lung Neoplasms Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: BMC Med Genomics Journal subject: GENETICA MEDICA Year: 2012 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google